Roberta DAmbrosio
Overview
Explore the profile of Roberta DAmbrosio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Costantino A, Piagnani A, Caccia R, Sorge A, Maggioni M, Perbellini R, et al.
Dig Liver Dis
. 2023 Nov;
56(6):1032-1038.
PMID: 38016894
Background: This diagnostic prospective study compared the feasibility and diagnostic accuracy of Pocket-size Ultrasound Devices (PUDs) against standard ultrasound (US) in detecting liver steatosis using the controlled attenuation parameter (CAP)...
12.
DAmbrosio R, Piccinelli S, Beccalli B, Spinetti A, Puoti M, Fagiuoli S, et al.
Liver Int
. 2023 Sep;
43(12):2645-2656.
PMID: 37715524
Background And Aim: The World Health Organization (WHO) goal of Hepatitis C Virus (HCV) elimination by 2030 rose awareness about the need of screening plans, worldwide. In Italy, graduated screening...
13.
Kondili L, Craxi L, Nava F, Babudieri S, DAmbrosio R, Marcellusi A, et al.
J Infect Dis
. 2023 Sep;
228(Suppl 3):S211-S220.
PMID: 37703346
Italy has had the highest prevalence of hepatitis C virus (HCV) infection and mortality from HCV-related liver cancer in Europe. Although direct-acting antivirals (DAA) were initially restricted to persons with...
14.
Pugliese N, Calvaruso V, Masarone M, DAmbrosio R, Battistella S, Licata A, et al.
Liver Int
. 2023 May;
43(7):1440-1445.
PMID: 37122194
Background: Glecaprevir and Pibrentasvir (G/P) determine high rates of sustained virological response (SVR) with optimal safety profile in patients with chronic hepatitis C virus (HCV) infection. The efficacy and safety...
15.
Pelusi S, Bianco C, Colombo M, Cologni G, Del Poggio P, Pugliese N, et al.
Liver Int
. 2023 Apr;
43(7):1593-1603.
PMID: 37035867
Background And Aims: Metabolic dysfunction (MD)-associated fatty liver disease has been proposed to identify individuals at risk of liver events irrespectively of the contemporary presence of other liver diseases. The...
16.
Kondili L, Quaranta M, Cavalletto L, Calvaruso V, Ferrigno L, DAmbrosio R, et al.
Dig Liver Dis
. 2023 Feb;
55(7):907-917.
PMID: 36775720
Background And Aims: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk...
17.
Aghemo A, Persico M, DAmbrosio R, Andreoni M, Villa E, Bhagat A, et al.
PLoS One
. 2023 Feb;
18(2):e0280165.
PMID: 36730135
Introduction: Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naïve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis...
18.
Aldinio G, DAmbrosio R, Perrone P, Castaldi S
Liver Int
. 2023 Jan;
43(4):945-946.
PMID: 36715094
No abstract available.
19.
Valenti L, Tripodi A, La Mura V, Pelusi S, Bianco C, Scalambrino E, et al.
JHEP Rep
. 2022 Oct;
4(12):100598.
PMID: 36313186
Background & Aims: The aim of this study was to examine the determinants of the interplay between liver damage and the coagulation balance in individuals at risk of non-alcoholic fatty...
20.
Iavarone M, Tosetti G, Facchetti F, Topa M, Er J, Hang S, et al.
Dig Liver Dis
. 2022 Oct;
55(2):160-168.
PMID: 36266209
Background And Aims: COVID-19 mRNA vaccines were approved to prevent severe forms of the disease, but their immunogenicity and safety in cirrhosis is poorly known. Method: In this prospective single-center...